Last updated: February 15, 2026
Market Overview
NDC 68462-0356 corresponds to Lenvatinib mesylate (brand name: Lenvima), a kinase inhibitor approved for the treatment of certain thyroid cancers, hepatocellular carcinoma (HCC), and renal cell carcinoma (RCC). The drug is marketed by Eisai Co., Ltd.
The global oncology drug market has experienced rapid growth, driven by increased cancer incidence and expanding indications for existing therapies. Lenvatinib's position relies on its effectiveness in conditions with significant unmet medical needs, particularly in thyroid cancer and advanced HCC.
Market Size and Growth
Current Market Size (2022-2023)
- The global oncology market was valued at approximately USD 150 billion in 2022.
- Lenvatinib's market share stems from its approved indications. In 2022, the drug generated roughly USD 600 million in worldwide sales, predominantly in the United States, Japan, and Europe.
- The US accounts for about 50-55% of global sales due to higher prevalence of thyroid and liver cancers and established guidelines endorsing lenvatinib.
Key Competitors
- Sorafenib (Nexavar)
- Tucatinib (Tukysa) for HCC
- Nivolumab (Opdivo)
- Cabozantinib (Cabometyx)
Lenvatinib competes mainly with sorafenib in HCC and with other tyrosine kinase inhibitors in thyroid and RCC settings.
Market Drivers
- Increasing incidence rates of thyroid, liver, and kidney cancers.
- Expanding indications for lenvatinib approved by FDA (e.g., endometrial carcinoma, follicular thyroid carcinoma).
- Growing adoption in combination regimens (e.g., lenvatinib plus pembrolizumab).
- Rising global healthcare expenditure on cancer treatments.
Price Analysis
Current Pricing
- In the US, the average wholesale price (AWP) per month is approximate USD 13,000–USD 15,000.
- Magnesium and infusion costs add to treatment expenses.
- The federal payer price (Medicare/Medicaid) adjusts for discounts, usually 20-30% below AWP, approximating USD 10,000–USD 12,000/month.
Cost Comparison
| Drug |
Approximate Monthly Cost |
Indication |
Notes |
| Lenvatinib (NDC 68462-0356) |
USD 12,000 |
Thyroid, HCC, RCC |
Market average |
| Sorafenib |
USD 9,500 |
HCC |
Slightly cheaper, broader indication |
| Cabozantinib |
USD 14,000 |
RCC |
Similar range |
Price Trends
- No significant observed price discounts for Lenvatinib since launch.
- Potential reductions due to biosimilars are unlikely as of now, given it is a small molecule and patent exclusivity.
Patent and Regulatory Status
- Patent protection was extended through 2027-2030 in key markets.
- Patent litigations or challenges may influence pricing strategies.
Future Price Projections
| Year |
Projected Price Range |
Assumptions |
| 2024 |
USD 11,500–USD 12,500 |
Stable manufacturing costs, no significant market disruptions |
| 2025 |
USD 11,000–USD 12,000 |
Entry of biosimilar or generics unlikely; price competition remains limited |
| 2026 |
USD 10,500–USD 11,500 |
Increased adoption in combination therapies |
Market Risks
- Patent expiration or litigation.
- Regulatory delays or additional indications influencing demand.
- Competitive spike from emerging therapies or biosimilars.
Key Takeaways
- The global market for lenvatinib is approximately USD 600 million with upward growth projections.
- US reimbursement prices for lenvatinib hover around USD 12,000 per month.
- Price stability is expected until patent expiry in 2027–2030.
- Competition from sorafenib and emerging combination therapies may influence future market dynamics.
- Tight indication-specific geographic and regulatory conditions will sustain current price levels.
FAQs
-
What are the primary factors influencing lenvatinib’s market share?
Regulatory approvals, clinical efficacy, safety profile, and competing therapies impact the drug's market share.
-
Are biosimilars expected to affect lenvatinib’s pricing?
As a small molecule, lenvatinib does not currently have biosimilars. Generic alternatives may influence pricing after patent expiry.
-
How does lenvatinib compare with sorafenib in pricing and efficacy?
Prices are similar, though lenvatinib’s efficacy in specific settings, like differentiated thyroid cancer, may be superior according to clinical trials.
-
What is the outlook for lenvatinib in emerging markets?
Growth depends on local approval, healthcare infrastructure, and pricing negotiations; market expansion is anticipated.
-
What are the primary risks to future price stability?
Patent challenges, increased competition, and regulatory changes could reduce future pricing margins.
Sources:
[1] IQVIA. (2023). Oncology Market Overview.
[2] FDA. (2022). Lenvatinib (Lenvima) approval details.
[3] AnalyzePharma. (2023). Oncology drug pricing trends.
[4] Company Earnings Reports. (2022–2023). Eisai Co., Ltd.
[5] MarketWatch. (2023). Cancer drug sales analysis.
